338 related articles for article (PubMed ID: 32507817)
41. Upfront thiotepa, busulfan, cyclophosphamide, and autologous stem cell transplantation for primary CNS lymphoma: a single centre experience.
Alimohamed N; Daly A; Owen C; Duggan P; Stewart DA
Leuk Lymphoma; 2012 May; 53(5):862-7. PubMed ID: 22023529
[TBL] [Abstract][Full Text] [Related]
42. Promising treatment results with blood brain barrier disruption (BBBD) based immunochemotherapy combined with autologous stem cell transplantation (ASCT) in patients with primary central nervous system lymphoma (PCNSL).
Kuitunen H; Tokola S; Siniluoto T; Isokangas M; Sonkajärvi E; Alahuhta S; Turpeenniemi-Hujanen T; Jantunen E; Nousiainen T; Vasala K; Kuittinen O
J Neurooncol; 2017 Jan; 131(2):293-300. PubMed ID: 27752883
[TBL] [Abstract][Full Text] [Related]
43. Consolidative Autologous Stem Cell Transplantation Versus Whole Brain Radiation in PCNSL; a Nationwide Analysis.
Samhouri Y; Mustafa Ali MK; Law J; Khan C; Wegner R; Lee ST; Lister J
Clin Lymphoma Myeloma Leuk; 2022 Oct; 22(10):735-743. PubMed ID: 35705438
[TBL] [Abstract][Full Text] [Related]
44. Have treatment protocols for primary CNS lymphoma advanced in the past 10 years.
Seidel S; Schlegel U
Expert Rev Anticancer Ther; 2019 Oct; 19(10):909-915. PubMed ID: 31594423
[No Abstract] [Full Text] [Related]
45. The role of upfront autologous stem cell transplantation in high-risk younger patients with primary central nervous system lymphoma.
Cho H; Chang JH; Kim YR; Kim SJ; Chung H; Park H; Lee JY; Jang JE; Kim Y; Kim SH; Yang WI; Suh CO; Cheong JW; Min YH; Kim JS
Br J Haematol; 2016 Aug; 174(3):444-53. PubMed ID: 27018207
[TBL] [Abstract][Full Text] [Related]
46. Treatment of primary CNS lymphoma (PCNSL) following successful treatment of systemic non-Hodgkin's lymphoma (NHL): a case series.
Chamberlain MC
J Neurooncol; 2013 May; 113(1):27-32. PubMed ID: 23456654
[TBL] [Abstract][Full Text] [Related]
47. Autologous Stem-Cell Transplantation for Primary Central Nervous System Lymphoma: Systematic Review and Meta-analysis.
Alnahhas I; Jawish M; Alsawas M; Zukas A; Prokop L; Murad MH; Malkin M
Clin Lymphoma Myeloma Leuk; 2019 Mar; 19(3):e129-e141. PubMed ID: 30584023
[TBL] [Abstract][Full Text] [Related]
48. A Comprehensive Assessment of Toxicities in Patients with Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using Thiotepa, Busulfan, and Cyclophosphamide Conditioning.
Scordo M; Bhatt V; Hsu M; Omuro AM; Matasar MJ; DeAngelis LM; Dahi PB; Moskowitz CH; Giralt SA; Sauter CS
Biol Blood Marrow Transplant; 2017 Jan; 23(1):38-43. PubMed ID: 27713090
[TBL] [Abstract][Full Text] [Related]
49. Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkologie OSHO-53 phase II study.
Montemurro M; Kiefer T; Schüler F; Al-Ali HK; Wolf HH; Herbst R; Haas A; Helke K; Theilig A; Lotze C; Hirt C; Niederwieser D; Schwenke M; Krüger WH; Dölken G
Ann Oncol; 2007 Apr; 18(4):665-71. PubMed ID: 17185743
[TBL] [Abstract][Full Text] [Related]
50. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL).
Bergner N; Monsef I; Illerhaus G; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Nov; 11():CD009355. PubMed ID: 23152274
[TBL] [Abstract][Full Text] [Related]
51. Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial.
Ferreri AJM; Cwynarski K; Pulczynski E; Fox CP; Schorb E; Celico C; Falautano M; Nonis A; La Rosée P; Binder M; Fabbri A; Ilariucci F; Krampera M; Roth A; Hemmaway C; Johnson PW; Linton KM; Pukrop T; Gørløv JS; Balzarotti M; Hess G; Keller U; Stilgenbauer S; Panse J; Tucci A; Orsucci L; Pisani F; Zanni M; Krause SW; Schmoll HJ; Hertenstein B; Rummel M; Smith J; Thurner L; Cabras G; Pennese E; Ponzoni M; Deckert M; Politi LS; Finke J; Ferranti A; Cozens K; Burger E; Ielmini N; Cavalli F; Zucca E; Illerhaus G;
Leukemia; 2022 Jul; 36(7):1870-1878. PubMed ID: 35562406
[TBL] [Abstract][Full Text] [Related]
52. Management and outcome of primary CNS lymphoma in the modern era: An LOC network study.
Houillier C; Soussain C; Ghesquières H; Soubeyran P; Chinot O; Taillandier L; Lamy T; Choquet S; Ahle G; Damaj G; Agapé P; Moluçon-Chabrot C; Amiel A; Delwail V; Fabbro M; Jardin F; Chauchet A; Moles-Moreau MP; Morschhauser F; Casasnovas O; Gressin R; Fornecker LM; Abraham J; Marolleau JP; Tempescul A; Campello C; Colin P; Tamburini J; Laribi K; Serrier C; Haioun C; Chebrek S; Schmitt A; Blonski M; Houot R; Boyle E; Bay JO; Oberic L; Tabouret E; Waultier A; Martin-Duverneuil N; Touitou V; Cassoux N; Kas A; Mokhtari K; Charlotte F; Alentorn A; Feuvret L; Le Garff-Tavernier M; Costopoulos M; Mathon B; Peyre M; Delgadillo D; Douzane H; Genet D; Aidaoui B; Hoang-Xuan K; Gyan E
Neurology; 2020 Mar; 94(10):e1027-e1039. PubMed ID: 31907289
[TBL] [Abstract][Full Text] [Related]
53. A prospective phase II trial of response adapted whole brain radiotherapy after high dose methotrexate based chemotherapy in patients with newly diagnosed primary central nervous system lymphoma-analysis of acute toxicity profile and early clinical outcome.
Adhikari N; Biswas A; Gogia A; Sahoo RK; Garg A; Nehra A; Sharma MC; Bhasker S; Singh M; Sreenivas V; Chawla R; Joshi G; Kumar L; Chander S
J Neurooncol; 2018 Aug; 139(1):153-166. PubMed ID: 29633112
[TBL] [Abstract][Full Text] [Related]
54. Controversies in the treatment of lymphoma with autologous transplantation.
Moskowitz AJ; Moskowitz CH
Oncologist; 2009 Sep; 14(9):921-9. PubMed ID: 19737999
[TBL] [Abstract][Full Text] [Related]
55. Autologous Stem Cell Transplantation in Central Nervous System Lymphoma: A Multicenter Retrospective Series and a Review of the Literature.
Dholaria BR; Kumar A; Azzuqua AG; Nishihori T; Kharfan-Dabaja MA; Tun HW; Ayala E
Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):e273-e280. PubMed ID: 30914301
[TBL] [Abstract][Full Text] [Related]
56. Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients Age 60 Years and Younger: Long-Term Results of the Randomized Phase II PRECIS Study.
Houillier C; Dureau S; Taillandier L; Houot R; Chinot O; Moluçon-Chabrot C; Schmitt A; Gressin R; Choquet S; Damaj G; Peyrade F; Abraham J; Delwail V; Gyan E; Sanhes L; Cornillon J; Garidi R; Delmer A; Al Jijakli A; Morel P; Waultier A; Paillassa J; Chauchet A; Gastinne T; Laadhari M; Plissonnier AS; Feuvret L; Cassoux N; Touitou V; Ricard D; Hoang-Xuan K; Soussain C;
J Clin Oncol; 2022 Nov; 40(32):3692-3698. PubMed ID: 35834762
[No Abstract] [Full Text] [Related]
57. Autologous stem cell transplant in recurrent or refractory primary or secondary central nervous system lymphoma using thiotepa, busulfan and cyclophosphamide.
Welch MR; Sauter CS; Matasar MJ; Faivre G; Weaver SA; Moskowitz CH; Omuro AM
Leuk Lymphoma; 2015 Feb; 56(2):361-7. PubMed ID: 24745937
[TBL] [Abstract][Full Text] [Related]
58. Analysis of Key Factors Associated with Response to Salvage High-Dose Methotrexate Rechallenge in Primary Central Nervous System Lymphoma with First Relapse.
Du P; Chen H; Shen L; Liu X; Wu X; Chen L; Cao A; Geng D
Curr Oncol; 2022 Sep; 29(9):6642-6656. PubMed ID: 36135091
[TBL] [Abstract][Full Text] [Related]
59. High-dose Thiotepa, Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplantation as Upfront Consolidation for Systemic Non-Hodgkin Lymphoma With Synchronous Central Nervous System Involvement.
Qualls D; Sullivan A; Li S; Brunner AM; Collier K; Hochberg E; Armand P; Batchelor TT; Chen YB; DeFilipp Z
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):884-888. PubMed ID: 28870642
[TBL] [Abstract][Full Text] [Related]
60. Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network.
Langner-Lemercier S; Houillier C; Soussain C; Ghesquières H; Chinot O; Taillandier L; Soubeyran P; Lamy T; Morschhauser F; Benouaich-Amiel A; Ahle G; Moles-Moreau MP; Moluçon-Chabrot C; Bourquard P; Damaj G; Jardin F; Larrieu D; Gyan E; Gressin R; Jaccard A; Choquet S; Brion A; Casasnovas O; Colin P; Reman O; Tempescul A; Marolleau JP; Fabbro M; Naudet F; Hoang-Xuan K; Houot R
Neuro Oncol; 2016 Sep; 18(9):1297-303. PubMed ID: 26951382
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
